VIDEO: Menin inhibitors a 'promising new class' of targeted therapy for AML
In this video, Eunice Wang, MD, discusses data presented at the ASH Annual Meeting and Exposition that validates menin inhibitors as a new class of targeted therapy for AML.
"We saw the expansion and further validation of menin inhibitors as a potentially novel and highly promising new class of targeted therapy for patients with acute myeloid leukemia characterized by KMG2A rearrangements or NMP1 mutations," Wang, said, noting a late-breaking phase 2 study that showed meaningful overall response rates for patients with relapsed/refractory KMT2A rearranged acute leukemia who received revumenib monotherapy.
“Clearly the menin inhibitors are moving forward,” Wang, associate professor of oncology, medicine, at Roswell Park Cancer Institute, said.
Reference:
- Jabbour E, et al. A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations. Presented at: ASH Annual Meeting and Exposition, Dec. 9-12, 2023; San Diego.
- Aldoss I, et al. Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study. Presented at: ASH Annual Meeting and Exposition, Dec. 9-12, 2023; San Diego.